Trials
2 active
3 in total · 2 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Neuromuscular Disease, Neuromuscular Diseases (NMD), Neurodegenerative Disease, Neurodegenerative Disease, Hereditary, Neurodegenerative Diseases, Neuromuscular Diseases, Nerve Disorders, Nervous System Disease and 13 more
- Main trialPhase 3
- “This study will be conducted to evaluate the efficacy and safety of a single dose of nexiguran ziclumeran (NTLA-2001) compared to placebo in participants with ATTRv-PN.”In the company’s words, NCT06672237 on ClinicalTrials.gov
- Other names
- nexiguran ziclumeran
Other drugs for Neuromuscular Diseases (NMD)
- AOC 1044Avidity Biosciences, Inc. · Phase 3
- Givinostat HydrochlorideItalfarmaco · Phase 3
- SGT-003Solid Biosciences Inc. · Phase 3
- Zeleciment RostudirsenDyne Therapeutics · Phase 3
- DeramiocelCapricor Inc. · Phase 3
- SatralizumabRoche · Phase 2
Coming up2
- Jul 2027Phase 3 trial completes · ClinicalTrials.gov
- Dec 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Jul 2027 | A Phase 3 Study of NTLA-2001 in ATTRv-PN | |
| Phase 3Recruiting | Dec 2027 | MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) | |
| Phase 1Completed | 12 Sep 2025 | Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026